NEW YORK (GenomeWeb) – After posting a 6 percent gain in January, the GenomeWeb Index rose nearly 5 percent in February, on par with the Dow Jones Industrial Average, and outperforming a 4 percent gain from the Nasdaq. The Index underperformed the Nasdaq Biotechnology Index, however, which gained 7 percent in February.

Stock performance in the February GenomeWeb Index was almost entirely positive, with 22 of the 26 stocks seeing gains and only four seeing losses. Many of the gains and losses in February were less dramatic than the ones last month, however.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Consulting company McKinsey says diagnostics companies will have to combine genomic data analysis, electronic medical records, effective reimbursement strategies, and regulatory compliance in order to win.

A new report has found that researchers in Africa are still heavily dependent on funding from organizations in the US, Europe, and China, Nature News says.

An article in The Atlantic argues that the progress being made in science isn't keeping pace with the money and time being spent on research.

In Science this week: a CRISPR screen identifies sideroflexin 1 as a requisite component of one-carbon metabolism, and more.